Engflag

Cosome

Quick links to important sections

Cosome

Cosome_FI

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cosome

Cosome is a multi-ingredient medicinal preparation classified as an Upper Respiratory Combination drug, formulated to provide comprehensive relief from the varied symptoms of the common cold, flu, and minor respiratory allergies.

Property Description
Active Ingredients Bromhexine, Chlorphenamine Maleate, Dextromethorphan Hbr, Paracetamol, Phenylephrine HCl, and others.
Form Oral Liquid (Syrup, Expectorant) and Oral Solid (Tablet).
Pharmacological Class Upper Respiratory Combination (Integrates Mucolytic, Antitussive, Antihistamine, Analgesic, and Decongestant classes).
Common Therapeutic Purpose Concurrent relief of fever, pain, cough, and nasal congestion.
Origin Synthetic/Chemically Derived.

Classification and Multi-Component Composition

As a combination product, Cosome differs from single-agent treatments by integrating several distinct synthetic active ingredients for oral administration. The core composition typically includes five key pharmacological classes that define its multi-action approach, including agents like Bromhexine, a mucolytic, and Dextromethorphan Hydrobromide, an antitussive. This comprehensive formulation is designed to target multiple pathways in respiratory discomfort. Combining these agents is a widely accepted method to address cough, pain, and fever concurrently.

Unique Features and General Purpose

The overall design of Cosome represents an approach to respiratory symptom management that addresses multiple symptoms simultaneously. A differentiating factor is the inclusion of the mucolytic agent, Bromhexine, which works to thin thick mucus, combined with the antitussive action of Dextromethorphan, distinguishing it from remedies that may only suppress the cough reflex. The inclusion of Paracetamol provides systemic pain and fever relief. The general purpose of Cosome is to mitigate the overall discomfort of temporary respiratory illness, facilitating patient comfort during a typical bout of the common cold or flu by addressing both localized symptoms and systemic malaise.

Regulatory References

  1. MedlinePlus

What side effects are possible with Cosome?

Adverse Reactions and Safety Profile

The official safety documentation for Cosome, a multi-component preparation, addresses potential effects across several body systems as classified by regulatory authorities (System-Organ Classes).

Commonly Documented Effects

Adverse reactions classified as very common or common in official labeling primarily affect the Nervous System and Gastrointestinal systems. These effects are largely driven by the antihistamine component, and include sedation, somnolence (drowsiness) (very common), dizziness, headache, and dry mouth (common).

System-Organ Class Common Adverse Reactions
Nervous System Disorders Sedation, Somnolence, Dizziness, Headache
Gastrointestinal Disorders Nausea, Dry mouth, Abdominal pain
Ocular Disorders Blurred vision

Serious Adverse Reactions (SARs) and Risks

The regulatory profile highlights rare but clinically significant adverse reactions. The most serious officially documented risk is acute liver failure, which is directly linked to Paracetamol component overdose and can be fatal. Severe, rare cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP), are also documented risks associated with both the analgesic and mucolytic agents.

Safety Restrictions and Special Populations

Safety limitations require specific caution in certain patient groups or contexts. Official documents state that older adults and children are more susceptible to neurological anticholinergic effects like confusion and paradoxical excitation. Caution is also required in individuals with pre-existing conditions such as hepatic impairment (due to reduced clearance and hepatotoxicity risk), severe renal impairment, narrow-angle glaucoma, and severe hypertension (due to the decongestant component).

Use is strictly restricted with, or within 14 days of stopping, Monoamine Oxidase Inhibitors (MAOIs), as explicitly stated in the labeling.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Cosome addresses the potential for overdose due to the combined toxicological profiles of its active ingredients, requiring specific emergency measures.

Documented Overdose Manifestations

Overdose presentations may include gastrointestinal distress (nausea, vomiting, abdominal pain), Central Nervous System (CNS) effects such as confusion, somnolence, excitation, agitation, and the potential for seizures. Autonomic and cardiovascular signs, including tachycardia, hypertension, and anticholinergic effects (like dry mouth and mydriasis), are also documented. Critical documented manifestations associated with the Paracetamol component, such as jaundice, pallor, and diaphoresis, are indicators of potential severe hepatic injury.

Severe Outcomes and Emergency Actions

The most severe documented outcome is hepatic necrosis progressing to hepatic failure, which is a life-threatening risk. Other severe documented complications include hypertensive crisis, ventricular arrhythmias, and serotonin syndrome.

Immediate medical advice must be sought in the event of any suspected overdose, even if the patient feels well. Hospital monitoring and evaluation are required. Management protocols officially describe the use of the specific antidote, N-acetylcysteine, to mitigate the time-critical risk of liver damage. Supportive and symptomatic measures are documented for managing CNS and cardiovascular instability, which can be heightened in pediatric and elderly patients.

Therapeutic Uses of Cosome

What Cosome Treats: Main Uses and Benefits

Cosome is commonly used across conditions presenting with acute episodes, such as the common cold, influenza (flu), and symptoms of minor respiratory allergies. Such multi-symptom treatments are designed to address a range of patient distress. Specifically, the medication is relevant for easing symptoms related to inflammatory or irritative states, including elevated temperature, minor aches, nasal congestion, cough, and excess secretions. This approach helps address symptom clusters that may become noticeable or difficult to tolerate during acute illness.

The medication is utilized where short-term symptomatic assistance is needed. It is often used during phases when symptoms become more noticeable, addressing a wide range of manifestations that create noticeable physiological strain. It is helpful in situations where multiple symptoms occur together and is relevant when supportive symptom management is appropriate.

“It provides support that helps ease the overall symptom burden during periods of heightened discomfort.”

By addressing symptoms that interfere with daily functioning, Cosome contributes to improved comfort and may assist with maintaining a sense of stability when symptoms are more noticeable.

Common Symptom Relief Areas

The medicine is commonly used to help with groups of symptoms that may become noticeable, including fever, pain, cough, and nasal congestion associated with temporary respiratory illness.

Regulatory References

  1. NIH MedlinePlus overview of Cold and Cough Medicines

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility for Cosome, based strictly on government regulatory guidelines for multi-component respiratory combinations.

Populations Prohibited from Use (Contraindicated)

Classification Rule
Absolute Contraindication Individuals with known hypersensitivity or allergy to any component must not use the medicine.
Drug-Interaction Contraindication Use is contraindicated if a patient is currently taking, or has taken within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI), due to the risk of a severe reaction.
Severe Comorbidity The medicine is contraindicated in patients with severe hypertension or severe coronary artery disease.

Age-Related Eligibility and Limitations

Age Group Eligibility Status
Children Under 4 to 6 Years Use is generally not recommended or contraindicated by regulatory bodies, as safety and efficacy are not established for infants and toddlers.
Older Adults (65+) Use requires caution, as older patients may be more susceptible to certain effects of the antihistamine and decongestant components.

Conditional Use and Restricted Populations

Condition Regulatory Status
Pregnancy/Lactation Generally not recommended; use should be assessed by a healthcare professional only if clearly needed. Components may pass into breast milk.
Organ Impairment Caution is required for patients with severe hepatic impairment (liver disease) or severe renal impairment (kidney disease).
Specific Comorbidities Caution is advised for those with Diabetes Mellitus, Hyperthyroidism, glaucoma (narrow-angle), or urinary retention due to an enlarged prostate.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail several critical interactions based on the multi-component nature of Cosome, involving pharmacokinetic and pharmacodynamic mechanisms.

Interaction Scope

Classification Interacting Agents & Restrictions
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs) (e.g., Linezolid). Formal prohibition due to severe risk of hypertensive crisis and Serotonin Syndrome.
Timing-Based Rules MAOIs require a mandatory 14-day separation period after discontinuation before Cosome may be administered.
Pharmacokinetic Alteration Potent CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine) are documented to inhibit the metabolism of Dextromethorphan, increasing its systemic exposure and risk of accumulation.
Pharmacodynamic Reinforcement Other CNS Depressants (e.g., Opioids, Sedative Hypnotics, Alcohol) increase the effect of sedation caused by the Chlorphenamine Maleate component.
Exposure and Toxicity Risk Alcohol is restricted due to additive CNS depression and a documented risk of Paracetamol-related hepatotoxicity, which is heightened in individuals with Hepatic Impairment or Chronic Alcoholism.
Cardiovascular Potentiation Other Sympathomimetics/Vasopressors reinforce the cardiovascular effects of Phenylephrine, including the risk of elevated blood pressure.

Regulatory Summary

The structure of the interaction profile is defined by these documented constraints. Combinations resulting in potentially life-threatening outcomes, such as co-administration with MAOIs, are formally contraindicated and require a strict timing separation. Other clinically significant interactions involve changes to drug concentration via metabolic enzymes and additive effects on the central nervous and cardiovascular systems, all as classified in government regulatory labeling.

Mechanism of Action

Central Influence on Reflex Arc and Thermoregulation

This mechanistic domain involves the actions of Paracetamol and Dextromethorphan, which influence specific CNS physiological pathways. Paracetamol selectively inhibits prostaglandin synthesis in the hypothalamus to reduce the level of Prostaglandin E2 ( PGE2) at the thermoregulatory set point. Dextromethorphan interacts with brainstem receptors, including NMDA and Sigma-1 (sigma1), to elevate the threshold of the cough reflex arc. These mechanisms combine to reduce signal transmission involved in thermoregulation, nociception, and the cough reflex arc.

Peripheral Airway Secretion and Vascular Tone Alteration

This domain targets the autonomic nervous and respiratory systems through the coordinated mechanisms of Phenylephrine, Chlorphenamine, and Bromhexine. Phenylephrine is an alpha1-Adrenoceptor agonist that directly induces vasoconstriction in the nasal vasculature, while Chlorphenamine acts as a competitive H1 antagonist to block histamine-driven increases in vascular permeability and glandular secretion. Bromhexine complements this by acting directly on the mucus structure, triggering the breakdown of viscous mucopolysaccharide fibers to facilitate natural mucociliary clearance. These mechanisms collectively alter vascular tone and the physical properties of airway secretions.

Dosage and Administration Information

Official Administration Guidelines for Cosome

Cosome, as a multi-component medicinal preparation, is administered according to specific protocols defined in product labeling and regulatory standards. Adherence to these guidelines, which establish the route, frequency, and dose limits, is essential for its correct use.

Administration Scope and Forms

Instruction Category Official Guideline
Route of Administration Exclusively Oral (swallowing the liquid or tablet).
Available Forms Oral Liquid (Syrup/Expectorant) and Oral Tablet (Solid Form).
Duration Constraint Intended for short-term use only, typically not to exceed 5 to 7 days of continuous self-treatment.

Standard Dosing and Frequency

Official labeling defines the following standardized regimens for symptomatic management, typically based on a 4 to 6-hour interval:

  • Adults and Children 12 years and older: The dose is usually 10 mL of liquid or 1 tablet every 4 to 6 hours, as needed. Dosing recommendations may vary based on specific formulation strength.
  • Maximum Limit: It is critical not to exceed the maximum daily dose specified on the label, which often restricts administration to no more than 6 doses in any 24-hour period.

Administration Conditions and Specific Populations

Instruction Category Procedural Rule
Timing Relative to Meals May be taken with or without food.
Dose Measurement Liquid doses must be measured accurately using the provided dosing device (cup or spoon).
Pediatric Use Use is not recommended for children under 6 years; a reduced dose is specified for children aged 6 to under 12 years, requiring careful adherence to label instructions.
Tablet Integrity Extended-release tablets must be swallowed whole and must not be crushed, cut, or chewed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cosome

Evidence for Use in Common Cold and Flu-like Symptoms

Research has examined multi-ingredient preparations like Cosome in the context of conditions associated with acute or disruptive episodes, such as the common cold and flu-like illnesses. These studies often take the form of short-term Randomized Controlled Trials (RCTs), where the medicine is compared against a non-active substitute (placebo) or other treatments. This research examined how symptoms change over time in healthy adults presenting with symptoms of recent onset.

The studies monitored patient-reported outcomes describing perceived discomfort and outcomes describing episodic or acute changes in a cluster of symptoms. These include changes in measurements for fever, pain and body aches, cough frequency and intensity, and nasal congestion. Findings from systematic reviews and pooled data described patterns where the change in overall symptom scores in the group receiving the multi-ingredient combination differed from the group receiving a placebo during the short study period.

Evidence for Relief of Minor Respiratory Allergy Symptoms

Research has also examined the antihistamine (like Chlorphenamine) and decongestant (like Phenylephrine) components of this type of medicine in trials assessing symptom patterns associated with minor respiratory allergies. Studies conducted during periods of increased symptom activity examined patient-reported outcomes for symptoms such as runny nose (rhinorrhea), sneezing, and nasal congestion. The evidence contributes to understanding the short-term effects on symptoms linked to irritative or inflammatory states.

Study Duration and Long-Term Follow-up

The majority of the core evidence for this class of medicine comes from studies where follow-up durations were short. Efficacy is typically monitored over a very short-term interval, often between 1 to 5 days, which aligns with the temporary nature of the common cold. Long-term effects are not fully established because the product is designed for short-term use during acute illness. The existing data is not structured to provide insight into repeated or prolonged administration over months or years.

Research in Special Populations

Research exploring these combination products primarily utilized healthy adults without significant underlying medical conditions. Consequently, the data for certain groups remain insufficient. Few data are available for children, particularly those under the age of six, where the use of many multi-component cough and cold medicines is not fully established and is often not recommended. The data gathered reflects the populations studied, meaning the applicability of these findings to individuals with more complex health profiles or those at the extremes of the age spectrum remains to be fully established.

Key Studies & References

  1. Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome
  2. Systemic review of randomized controlled trials of over the counter cough medicines for acute cough in adults
  3. Review of cough and cold medicines in children - Therapeutic Goods Administration (TGA)

Frequently Asked Questions (FAQ)

Common questions about Cosome (FAQ)

Q: What is the generic name for Cosome?

Cosome is described in official documents as a multi-ingredient product, which means it does not have a single generic name like a single-agent medicine. Its formulation consists of five generic components, including Paracetamol (analgesic), Dextromethorphan (antitussive), Phenylephrine (decongestant), Chlorphenamine (antihistamine), and Bromhexine (mucolytic).

Q: How is Cosome different from other medications used for the same condition?

Official product information describes Cosome as a multi-ingredient combination, integrating five distinct types of active components. This comprehensive formulation includes a mucolytic agent, an antitussive, an antihistamine, an analgesic, and a decongestant. The product is formulated this way to target multiple cold and flu symptoms concurrently, which is a differentiating factor from simpler remedies.

Q: How long does it usually take to notice the effects of Cosome?

Pharmacokinetic data in official drug monographs indicate that the analgesic (pain-relieving) effect of the Paracetamol component is typically noticed within 30 to 60 minutes after administration. The onset of action for the other components, such as the decongestant and antitussive, varies based on their specific pharmacological profiles.

Q: What is the typical length of treatment with Cosome?

According to official product labeling, this medicine is intended for short-term use only, typically to manage symptoms during an acute illness like a cold. Regulatory research has focused on short-term efficacy, meaning that long-term effects and risks over many months or years are not fully established. Repeated or prolonged use is not what the medicine is designed for.

Q: Is Cosome safe for people who have a history of heart conditions?

Regulatory contraindications state that Cosome must not be used by individuals with severe hypertension (high blood pressure) or severe coronary artery disease. Regulatory documents note that caution is required for individuals with other pre-existing heart conditions because the decongestant component, Phenylephrine, has the potential to elevate blood pressure.

Q: Are there any warnings about driving or operating machinery while taking Cosome?

Official warnings specify that due to the potential for drowsiness, sedation, or dizziness, the ability to drive or operate heavy machinery may be impaired, and caution is required. This regulatory warning should be considered before engaging in activities that require full mental alertness.

Q: Do the side effects of Cosome typically go away after a few weeks?

Given that the medicine is intended for short-term use only, typically 5 to 7 days, side effects are typically noted to resolve shortly after the treatment period concludes. Official information does not describe the persistence of common side effects over a period of several weeks.

Q: Can Cosome cause issues with sleep or insomnia?

Official warnings state that while this medicine commonly causes drowsiness (somnolence) due to the antihistamine component, it may also have stimulant effects. The decongestant component, Phenylephrine, can potentially cause nervousness, excitability, or difficulty sleeping in some individuals. This is mentioned in regulatory warnings regarding nervous system effects.

Q: Does Cosome have a 'Black Box Warning' from the FDA or similar agency?

According to official product labeling, this medicine carries serious risk warnings, most notably the potential for acute liver failure due to the Paracetamol component. The specific presence of a Black Box Warning, which is a specialized regulatory designation, must be confirmed by reviewing the full official drug labeling published by regulatory authorities.

Q: Is Cosome addictive or does it carry a risk of dependence?

Officially, this medicine is not classified as a controlled substance for standard therapeutic use. However, regulatory warnings note that Dextromethorphan, an active ingredient, has been associated with a risk of psychological dependence when misused chronically in high doses.

Q: What happens if you miss a dose of Cosome?

The standard procedure outlined in the administration guidance indicates that if a dose is missed, it can be taken when remembered, unless it is nearly time for the next scheduled dose. The guidance emphasizes that a double dose should not be taken to compensate for the missed one.

Q: Can I safely take Cosome with over-the-counter pain relievers like ibuprofen?

Regulatory warnings highlight that taking this medicine with any other product containing Paracetamol is strictly contraindicated due to the risk of overdose. Combining Paracetamol with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen also requires caution, as described in the official warnings.

Q: Does Cosome interact with caffeine?

Official warnings and drug safety guidance suggest that the decongestant component, Phenylephrine, is a stimulant. Combining this medicine with caffeine may lead to an increase in stimulant-related side effects such as nervousness, restlessness, or an increased heart rate.

Q: Does the Grapefruit Effect apply to Cosome?

The official product information indicates that the metabolism of one active ingredient, Dextromethorphan, can be slowed by certain medications or substances that inhibit the CYP2D6 enzyme. Due to this complex metabolic pathway, regulatory guidance indicates that definitive advice on potential food or drink interactions (like grapefruit) should be obtained from a healthcare provider.

Q: Will taking Cosome make me feel 'high' or different?

Regulatory and public health guidance emphasizes that this product is required to be used strictly as directed on the label to prevent misuse. Dextromethorphan, one of the active ingredients, has been associated with effects like euphoria or altered mental states if taken in doses exceeding the maximum recommended limit.

Q: What happens if I accidentally take two doses of Cosome?

Taking more than the maximum recommended dose, even accidentally, can lead to overdose symptoms. Due to the Paracetamol content, this is a serious risk. Official warnings describe the safety protocol for overdose, which includes immediately contacting emergency medical services or a Poison Control Center for guidance.

Q: Is Cosome safe for pets if accidentally ingested?

The official storage instructions require the medicine to be kept strictly out of the sight and reach of children and pets. Official safety instructions state that if an animal accidentally ingests the medicine, the protocol requires contacting a veterinarian or an animal Poison Control Center immediately, as the components can be harmful to animals.

Q: Are there any known genetic factors that affect how a person responds to Cosome?

Regulatory information on Dextromethorphan indicates that an individual's response can be affected by genetic differences in how the body metabolizes the drug using the CYP2D6 enzyme. Individuals who are 'poor metabolizers' for this enzyme may experience increased systemic exposure to the active ingredient.

Q: How many phases of clinical trials did Cosome go through before approval?

As a multi-component product, approval is generally based on the established safety and efficacy data for its individual components. Clinical studies often take the form of short-term trials that compare the combination product against a placebo or a single component, frequently classified as Phase IV trials post-marketing.

Q: Why is Cosome sometimes prescribed for conditions other than its main approved use?

The official labeling for Cosome, as published by regulatory authorities, provides information only for the approved indications for which the drug was studied and sanctioned. While healthcare professionals may sometimes use medicines outside of their approved indications, all claims and purposes stated in the official documentation relate solely to its approved uses.

Q: What are the potential long-term risks of taking Cosome for many years?

According to official product labeling, this medicine is intended for short-term use only, typically to manage symptoms during an acute illness like a cold. Regulatory research has focused on short-term efficacy, meaning that long-term effects and risks over many months or years are not fully established. Repeated or prolonged use is not what the medicine is designed for.

How should Cosome be stored and disposed of?

The official labeling for Cosome requires specific handling and storage to maintain product stability.

Storage Requirements

The medicine must be stored at room temperature, which typically means a temperature not exceeding 30 C. It is mandatory to protect the medication from excess heat and moisture and to not freeze the product. The container must be kept tightly closed in its original packaging.

A critical requirement is to store Cosome out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Cosome must be disposed of safely. The preferred method is returning the medication through a drug take-back program. If a take-back option is unavailable, the regulatory-approved method is to remove the medicine from its container, mix it with an unappealing substance (like dirt or used coffee grounds), seal the mixture in a bag, and discard it in the household trash. Personal information should be removed from the original packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cosome found in:

A-Z Index: